Therapy Detail

Therapy Name Olaparib
Therapy Description

Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer, germline BRCA-mutated and ERBB2 (HER2)-negative breast cancer, and advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Olaparib Lynparza AZD2281|KU-0059436 PARP Inhibitor (Pan) 17 Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer, germline BRCA-mutated and ERBB2 (HER2)-negative breast cancer, and advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer no benefit Olaparib Phase II Actionable In a Phase II clinical trial, treatment with Lynparza (olaparib) did not result in clinical activity in colorectal cancer patients that had progressed on prior standard therapy, including both microsatellite-stable patients and those that demonstrated high microsatellite instability (PMID: 26786262). 26786262
BRCA1 mutant fallopian tube cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 mutant Her2-receptor negative breast cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622). 28578601
BRCA2 mutant fallopian tube cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA1 mutant peritoneum cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 inact mut breast cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467). 20609467
IDH1 R132H Advanced Solid Tumor sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839). 28148839
MET dec exp triple-receptor negative breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812). 26779812
ATM inact mut prostate cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020). 26510020
ATM inact mut mantle cell lymphoma sensitive Olaparib Preclinical - Cell line xenograft Actionable In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657). 20739657
Unknown unknown brain stem glioma not applicable Olaparib Preclinical - Cell culture Actionable In a preclinical study, Lynparza (olaparib) resulted in decreased cell viability of some diffuse intrinsic pontine glioma cell lines in culture (PMID: 26351319). 26351319
ATM mutant prostate cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322). detail...
BRCA1 wild-type triple-receptor negative breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative breast cancer cell lines expressing wild-type BRCA1 under hypoxic conditions (PMID: 25193512). 25193512
CBLC dec exp breast cancer predicted - sensitive Olaparib Preclinical Actionable In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215). 25883215
IDH1 R132H colon carcinoma sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839). 28148839
BRCA1 loss breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287). 27454287
Unknown unknown astrocytoma not applicable Olaparib Preclinical - Cell culture Actionable In a preclinical study, Lynparza (olaparib) resulted in decreased cell viability of some pediatric high grade astrocytoma cell lines in culture (PMID: 26351319). 26351319
BRCA1 mutant Her2-receptor negative breast cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622). 28578601
ATM del KRAS G12D lung adenocarcinoma sensitive Olaparib Preclinical Actionable In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999). 28363999
BRCA2 mutant peritoneum cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA1 C61G TP53 loss breast cancer decreased response Olaparib Preclinical Actionable In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724). 22172724
ARID1A Q456* colorectal cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) inhibited proliferation and colony formation of a colorectal cancer cell line harboring ARID1A Q456* in culture (PMID: 26069190). 26069190
BRCA1 L1795Pfs*3 breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) inhibited growth of human breast cancer cells harboring BRCA1 L1795Pfs*3 (referred to as BRCA1 5382insC) in culture, and resulted in prolonged overall survival in transgenic mouse models of breast cancer (PMID: 27454287). 27454287
STAG2 dec exp colorectal cancer sensitive Olaparib Preclinical Actionable In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817). 24356817
BRCA1 E23Vfs*17 breast cancer decreased response Olaparib Preclinical - Pdx & cell culture Actionable In a preclinical study, breast cancer cells harboring BRCA1 E23Vfs*17 (referred to as BRCA1 185delAG) demonstrated reduced sensitivity, developed resistance to Lynparza (olaparib) in culture and in patient-derived xenograft models due to the expression of a RING-less form of Brca1 (PMID: 27454287). 27454287
BRCA2 mutant breast cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467). 20609467
BRCA2 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 mutant ovarian cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org). detail...
BRCA2 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662). 26187614 25366685
BRCA2 mutant ovarian cancer sensitive Olaparib Preclinical - Pdx Actionable In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693). 21097693
BRCA2 mutant ovarian cancer sensitive Olaparib Phase III Actionable In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either mutant BRCA1 or mutant BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353). 28754483
ATM inact mut lymphocytic leukemia sensitive Olaparib Preclinical - Patient cell culture Actionable In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657). 20739657
BRCA1 mutant breast cancer sensitive Olaparib Phase II Actionable In a Phase II trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA1 mutations, with an objective response rate of 50% (9/18) in the maximum tolerated dose cohort and 19% (3/16) in the lower dose cohort (PMID: 20609467). 20609467
BRCA1 mutant triple-receptor negative breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512). 25193512
BRCA1 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662). 26187614 25366685
BRCA1 mutant ovarian cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org). detail...
BRCA1 mutant ovarian cancer sensitive Olaparib Phase III Actionable In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either mutant BRCA1 or mutant BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353). 28754483
BRCA1 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
STAG2 S653* glioblastoma multiforme sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 21852505 24356817
STAG2 N357fs glioblastoma multiforme sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 24356817
CBLC dec exp osteosarcoma predicted - sensitive Olaparib Preclinical Actionable In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215). 25883215
Unknown unknown prostate cancer not applicable Olaparib Phase II Actionable In a Phase II clinical trial, 86.7% (13/15) of metastatic castration-resistant prostate cancer patients with mutations in DNA repair genes demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322). detail...
IDH1 R132C sarcoma sensitive Olaparib Preclinical - Cell line xenograft Actionable In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839). 28148839
BRCA2 loss prostate cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020). 26510020
ARID1A dec exp breast cancer sensitive Olaparib Preclinical Actionable In a preclinical study, Lynparza (olaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190). 26069190
ATM inact mut chronic lymphocytic leukemia sensitive Olaparib Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived chronic lymphocytic leukemia cells with inactivating mutations in ATM, that had been induced to proliferate in culture, demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to ATM wild-type cells (PMID: 20739657). 20739657
BRCA1 wild-type breast cancer resistant Olaparib Preclinical Actionable In a preclinical study, BRCA1 proficient transgenic mouse models of breast cancer did not respond to Lynparza (olaparib) treatment (PMID: 27454287). 27454287
Clinical Trial Phase Therapies Title Recruitment Status
NCT02476968 FDA approved Olaparib To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer Active, not recruiting
NCT01445418 Phase I Olaparib Carboplatin AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer Completed
NCT02576444 Phase II MK-1775 + Olaparib Olaparib Olaparib + Vistusertib AZD5363 + Olaparib OLAParib COmbinations Recruiting
NCT03742895 Phase II Olaparib Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002) Recruiting
NCT03286842 Phase III Olaparib To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. Active, not recruiting
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Recruiting
NCT03317392 Phase Ib/II Olaparib Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Recruiting
NCT02987543 Phase III Olaparib Enzalutamide Abiraterone Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Active, not recruiting
NCT02282020 Phase III Olaparib Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments. Active, not recruiting
NCT03022409 Phase I Olaparib AZD6738 A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting
NCT03233204 Phase II Olaparib Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting
NCT02677038 Phase II Olaparib Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting
NCT02446704 Phase Ib/II Olaparib Temozolomide Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Recruiting
NCT03682289 Phase II AZD6738 + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting
NCT03263650 Phase II Cabazitaxel + Carboplatin Olaparib Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting
NCT03402841 Phase III Olaparib Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) Recruiting
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Recruiting
NCT03570476 Phase II Olaparib Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer Recruiting
NCT03330847 Phase II MK-1775 + Olaparib Olaparib AZD6738 + Olaparib To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Recruiting
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02511795 Phase I Adavosertib Olaparib AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors Recruiting
NCT03375307 Phase II Olaparib Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects Recruiting
NCT02571725 Phase Ib/II Tremelimumab Olaparib PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Suspended
NCT03012321 Phase II Abiraterone + Prednisone + Olaparib Abiraterone + Prednisone Olaparib Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects Recruiting
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting
NCT03432897 Phase II Olaparib BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) Recruiting
NCT03079687 Expanded access Olaparib Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Approved for marketing
NCT02184195 Phase III Olaparib Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Active, not recruiting
NCT02588105 Phase I Olaparib AZD0156 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Recruiting
NCT01844986 Phase III Olaparib Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Active, not recruiting
NCT03085147 Olaparib A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting
NCT02208375 Phase Ib/II Olaparib Capivasertib Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer Active, not recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Nivolumab + Ipilimumab Vemurafenib + Cobimetinib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT03532880 Phase I Olaparib A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer Recruiting
NCT03579316 Phase II Olaparib MK-1775 + Olaparib Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT03598257 Phase II Olaparib Radiation Therapy With or Without Olaparib in Treating Participants With Inflammatory Breast Cancer Recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Olaparib Selumetinib Ensartinib Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas Recruiting
NCT01972217 Phase II Prednisone Abiraterone Olaparib Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer Active, not recruiting
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Active, not recruiting
NCT03448718 Phase II Olaparib Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting
NCT03344965 Phase II Olaparib Olaparib In Metastatic Breast Cancer Recruiting
NCT02893917 Phase II Cediranib + Olaparib Olaparib Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Recruiting
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting
NCT03047135 Phase II Olaparib Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Recruiting
NCT02502266 Phase II Topotecan Paclitaxel Doxorubicin Olaparib Cediranib Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02489006 Phase II Olaparib A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Recruiting
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + MEDI4736 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Recruiting
NCT03531840 Phase II Olaparib Olaparib in People With Malignant Mesothelioma Recruiting
NCT02392676 Phase III Olaparib Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations Withdrawn
NCT02561832 Phase I Cyclophosphamide Olaparib Carboplatin A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer Terminated
NCT02446600 Phase III Paclitaxel Doxorubicin Gemcitabine Carboplatin Olaparib Cediranib Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT03167619 Phase II Durvalumab + Olaparib Olaparib Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) Recruiting